NDAORALFOR SUSPENSION
Approved
May 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
18
Data completeness
7/8 — Comprehensive
LOKELMA (sodium zirconium cyclosilicate) by AstraZeneca is (sodium zirconium cyclosilicate) is a non-absorbed zirconium silicate that preferentially captures potassium in exchange for hydrogen and sodium. First approved in 2018.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOKELMA (sodium zirconium cyclosilicate) is an oral, non-absorbed zirconium silicate that treats hyperkalemia by selectively binding potassium in the gastrointestinal tract and increasing fecal excretion. The drug works through a preferential ion-exchange mechanism that captures potassium in exchange for hydrogen and sodium, reducing serum potassium levels without systemic absorption.
$0.205BPart D
Peak9.3 years to LOEPeak-cycle product with $205M in annual Part D spending indicates established commercial infrastructure and mature team, likely focused on market maintenance and optimization rather than expansion.
Mechanism of Action
(sodium zirconium cyclosilicate) is a non-absorbed zirconium silicate that preferentially captures potassium in exchange for hydrogen and sodium. In vitro , LOKELMA has a high affinity for potassium ions, even in the presence of other cations such as calcium and magnesium. LOKELMA increases fecal…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (18)
VITALIZE.Use and Effectiveness of Sodium Zirconium Cyclosilicate (LokelmaTM) in the Real-world Setting in Spain
Started Nov 2024
232 enrolled
Hyperkalaemia
Sodium Zirconium Cyclosilicate to Allow Liberal Fruit and Vegetable Intake for Patients With CKD Stage 3b and 4
Started Apr 2024
16 enrolled
HyperkalemiaDiet ModificationChronic Kidney Disease+1 more
A National, Multicenter, Prospective, Observational Study to Assess Patient Characteristics, Treatment Algorithms and Disease Management of Hyperkalaemia Patients With Chronic Kidney Disease or Under Dialysis or With Heart Failure, Treated With Sodium Zirconium Cyclosilicate in Greece
Started Feb 2024
125 enrolled
Hyperkalaemia
A Prospective, Randomized, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia
Started Apr 2022
88 enrolled
Hyperkalemia
Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study
Started Mar 2022
186 enrolled
HyperkalaemiaChronic Kidney Disease
Worked on LOKELMA at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.